Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QCC 374

Next Previous
X
Search
Drug Profile

QCC 374

Alternative Names: NVP-QCC374; QCC374

Latest Information Update: 04 Mar 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antihypertensives
  • Mechanism of Action Epoprostenol agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pulmonary arterial hypertension

Most Recent Events

  • 30 Dec 2020 Discontinued - Phase-II for Pulmonary arterial hypertension in USA, South Korea, Germany, United Kingdom (Inhalation) (Novartis pipeline, December 2020)
  • 06 Nov 2018 Novartis completes a phase II trial in Pulmonary arterial hypertension in Germany, United Kingdom and USA (NCT02939599) (EudraCT2016-001411-20)
  • 01 Feb 2018 Novartis Pharmaceuticals initiates enrolment in a phase IIa extension trial for Pulmonary arterial hypertension in Germany and United Kingdom (Inhalation) (NCT02939599)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top